Abstract:HR‐based fertility‐sparing therapy showed an effective and safe response. Patients with EEC and a BMI ≤28 kg/m2 had higher CR, pregnancy, and live birth rates. Live birth rates remain to be improved by providing medical guidance and encouragement. Introduction Our objective was to conduct a systematic review and meta‐analysis of studies evaluating the oncological and reproductive outcomes of patients with endometrial atypical hyperplasia (AH) and endometrioid endometrial cancer (EEC) undergoing conservative therapy with hysteroscopic resection (HR). Material and methods This study followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement for systematic reviews and meta‐analyses. The study strictly followed the methodological framework proposed by the Cochrane Handbook and was retrospectively registered in PROSPERO (CRD42023469986). Searches were conducted in PubMed, Embase, and the Cochrane Library, from inception to October 10, 2023. A checklist based on items of the Newcastle–Ottawa Scale and the Methodological Index for Non‐randomized Studies was used for quality assessment. The primary end points for this meta‐analysis were complete response (CR), pregnancy, and live birth rates following HR‐based therapy in patients with EEC or AH. The secondary end point was the recurrence rate (RR). Results Twenty‐one articles involving 407 patients with clinical stage IA, low or intermediate grade, EEC, and 444 patients with AH managed with HR‐based conservative treatment were included for this systematic review. CR to HR‐based conservative therapy was achieved in 88.6% of patients with EEC and 97.0% of patients with AH. Of these, 30.6% and 24.2%, respectively, had live births. The overall pooled disease RR was 18.3% and 10.8% in patients with EEC and AH, respectively. Further subset analyses revealed that EEC patients with body mass index (BMI) ≤28 kg/m2 had higher CR rates as well as higher chances of pregnancy and live birth (91.6% CR, 32.9% pregnancy, 31.1% live birth) compared with patients with BMI >28 kg/m2 (86.4% CR, 28.4% pregnancy, 23.0% live birth). The HR followed by oral progestogen subgroup had higher CR rates and higher chances of pregnancy and live birth (91.8% CR, 36.3% pregnancy, 28.2% live birth) than the HR followed by the levonorgestrel intrauterine system subgroup (82.5% CR, 25.3% pregnancy, 16.3% live birth). Conclusions Hysteroscopic resection followed by progestins appears to be a promising choice for fertility‐sparing treatment in young patients with AH and EEC, with effective and safe responses. The live birth rate remains to be improved by providing medical guidance and encouragement.

Hysteroscopic Curettage Followed by Megestrol Acetate Plus Metformin As a Fertility-Sparing Treatment for Women with Atypical Endometrial Hyperplasia or Well-Differentiated Endometrioid Endometrial Carcinoma

A Prospective Study of Fertility-Sparing Treatment with Megestrol Acetate Following Hysteroscopic Curettage for Well-Differentiated Endometrioid Carcinoma and Atypical Hyperplasia in Young Women

Fertility-preserving Treatment and Pregnancy Outcomes in the Early Stage of Endometrial Carcinoma.

Metformin Plus Megestrol Acetate Compared with MA Alone As Fertility-Sparing Treatment in Patients with Atypical Endometrial Hyperplasia and Well-Differentiated Endometrial Cancer: a Randomised Controlled Trial

Treatment Efficiency of Comprehensive Hysteroscopic Evaluation and Lesion Resection Combined with Progestin Therapy in Young Women with Endometrial Atypical Hyperplasia and Endometrial Cancer.

A Phase Ⅱ Study of Fertility-Sparing Treatment with Megestrol Acetate for Endometrial Carcinoma and Atypical Hyperplasia in Young Women

[Effects of Pathological Assessment of Endometrial Tissue in Fertility-Sparing Treatment with Progestin for Endometrial Carcinoma of Stage I a and Complex Atypical Hyperplasia].

Metformin plus megestrol acetate compared with megestrol acetate alone as fertility‐sparing treatment in patients with atypical endometrial hyperplasia and well‐differentiated endometrial cancer: a randomised controlled trial

Oncological and reproductive outcomes of endometrial atypical hyperplasia and endometrial cancer patients undergoing conservative therapy with hysteroscopic resection: A systematic review and meta‐analysis

Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy

Efficacy and prognosis of fertility-preserved hysteroscopic surgery combined with progesterone in the treatment of complex endometrial hyperplasia and early endometrial carcinoma

Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy

Conservative Management of Grade 2 Stage IA Endometrial Carcinoma and Literature Review.

Clinicopathological Analysis Of Fertility-Sparing Treatment And Pregnancy Outcomes In Young Women With Early-Stage Endometrial Carcinoma

Oncologic and Reproductive Outcomes after Fertility‐sparing Management with Oral Progestin for Women with Complex Endometrial Hyperplasia and Endometrial Cancer

EP657 the Risk Factors and Therapeutic Regimens Analyses in the Fertility-Sparing Treatment of Refractory Endometrial Atypical Hyperplasia and Endometrial Cancer

Gonadotropin-Releasing Hormone Agonist Based Fertility-Sparing Treatment in Women with Endometrial Carcinoma or Atypical Endometrial Hyperplasia

Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia

Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma

Prognostic Factors of Oncological and Reproductive Outcomes in Fertility-Sparing Treatment of Complex Atypical Hyperplasia and Low-Grade Endometrial Cancer Using Oral Progestin in Chinese Patients

Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity